SCHEMBL32674502

SCHEMBL32674502

COc1ccc(Cn2c(=O)oc3ccc(Cc4nnn(-c5ccccc5)n4)c(F)c32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.36
▸ MIF P14174 3/20 0.35
▸ CD74 P04233 2/20 0.35
▸ FAAH O00519 2/20 0.35
▸ MGLL Q99685 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ P2RX4 Q99571 1/20 0.34
▸ RGS4 P49798 1/20 0.34
▸ RGS8 P57771 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ CDC25A P30304 1/20 0.34
▸ CDC25B P30305 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32674300 0.79 PLA2G2A (0.42) MAPTMIFCD74MEN1KMT2A
SCHEMBL32674374 0.76 KMO (0.45) MAPTMIFCD74MEN1KMT2A
SCHEMBL32674486 0.74 ALDH1A1 (0.41) MAPTMIFCD74MEN1KMT2A
SCHEMBL32674120 0.73 MIF (0.41) MIFCD74KMT2AALDH1A1HTT
SCHEMBL32674412 0.70 HPGD (0.39) MAPTKDM4EALDH1A1HPGD
SCHEMBL32674298 0.69 CRBN (0.36) ALDH1A1
SCHEMBL16099478 0.65 POLB (0.51) MAPTMIFCD74MEN1KMT2A
SCHEMBL16101686 0.65 MEN1 (0.54) MAPTMIFCD74MEN1KMT2A
SCHEMBL32674408 0.64 LMNA (0.45) MAPTMIFCD74POLBKDM4E
SCHEMBL32674271 0.64 MAPT (0.47) MAPTMIFCD74ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565492-B2 Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof TRIANA BIOMEDICINES, INC. (US) 2026-03-03 — — US disclosed
US-20260042752-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2026-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042752-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF ALK, NTRK1, NTRK3 MAPT 43/4885MIF 4562/4885CD74 3307/4885
US-12565492-B2 Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof ALK, NTRK3, NTRK1 MAPT 380/4885MIF 3616/4885CD74 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback